Article -> Article Details

Adenomyosis is defined as a medical condition in which the inner lining of the uterus (also known as the endometrium) breaks through the muscle wall of the uterus (the myometrium). The treatment of this medical problem is called adenomyosis treatment. A new report on the global adenomyosis treatment market, published by Market Research Future (MRFR), states that this market can visualize progress at 4.1% CAGR during the forecast period (2018-2023). In terms of value, the market can be worth USD 291.5 Mn by the end of the forecast period.

The biggest driver for the global adenomyosis treatment market growth is the global prevalence of adenomyosis. The increasing awareness about adenomyosis as well as its treatment is boosting the global adenomyosis treatment market by creating the demand, supply, and sales for new drugs and therapies, along with advanced medical technology-focused towards the adenomyosis. Hence, new opportunities are arising for market growth. During the forecast period, increased funding for research development (RD) to develop more advanced products (medical devices) is expected to reflect favorably on the market. However, the market in developing countries can face hurdles as many people are not aware of this medical problem.

Market Segmentation

The global adenomyosis treatment market segmentation encompasses diagnosis, type, and treatment. MRFR’s take on the market marks various facets of the market in-depth.

The diagnosis-based segmentation of this market covers endometrial biopsy, magnetic resonance imaging (MRI), ultrasound, and others. The ultrasound segment has been sub-segmented into transabdominal ultrasound and endovaginal ultrasound which is also known as transvaginal ultrasound.

By type, the market includes adenomyoma, diffuse, focal, and others.

By treatment, the market covers anti-inflammatory drugs, hormone medications, and hysterectomy. The anti-inflammatory drugs segment has been sub-segmented into Advil, ibuprofen, Motrin ibuprofen (Motrin IB), and others. The hormone medications segment has been sub-segmented into aromatase inhibitors and Gonadotropin-releasing hormone (GnRH) agonists. The hysterectomy segment radical hysterectomy, supracervical hysterectomy (also known as a subtotal hysterectomy), and total hysterectomy.  

Regional Segmentation

A geographical outlining of the global adenomyosis treatment market covers the Americas (North America South America), Asia Pacific, Europe, and the Middle East Africa (MEA).

The Americas is the biggest regional market as North America alone has the potential of becoming a powerful regional market. Due to the advanced medical facilities being available in the USA North America is a larger regional market segment compared to South America. North America is the largest regional market segment due to the rapid adoption of new drugs and therapies. Continuous innovation on the technological front and heavy use of technology in the medical sector boost market in this region. USA and Canada are generating the maximum revenue in this region.

Europe is the second-largest regional market as many important market players are based in Europe. Due to the reasons the same as in The Americas, Western Europe is a bigger market compared to Eastern Europe. The major market share comes from France, Germany, Spain, Italy, and the UK.

The Asia Pacific region is an important regional market due to improving medical sector and stable technological progress. In this report, this regional market has been segmented into Asia and the Pacific. In Asia, the key country-specific markets are China, India, Japan, and South Korea. An observation of the remaining countries in Asia and the Pacific region featured in this report calculates the additional market revenue from some other countries.

In the MEA region, the market has been slow due to limited availability of advanced medical facilities. Countries focused in the report include Egypt, Saudi Arabia, and the UAE.

Key Players

Big players in the global adenomyosis treatment market are Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson Johnson Consumer Inc. (USA), Merck KGaA (Germany), Novartis (Switzerland), Pfizer Inc. (USA) and Speciality European Pharma (UK).